Glycostem to present at the 18th CIMT Annual Meeting virtually with etalk presentation: Ex vivo expanded NK cells show potent anti-tumour activity against melanoma.
Glycostem to present at virtual event Stability V: Challenges of in-use stability demonstration hosted by Joint Pharmaceutical Analysis Group, to talk about in use stability considerations for large molecules.
Glycostem to participate the Oppenheimer 31st Annual Healthcare Conference, a virtual investor event, on Wednesday, March 17, 2021. Our CEO Troels Jordansen will provide an overview of the company and progress. Glycostem will host one-on-one meetings with investors during the event.
Glycostem will present on the virtual 10th Annual Global Healthcare Conference hosted by SVB Leerink on 23rd Feb, 2021, to share the latest updates of our company and products, and host one-on-one meetings with investors.
Glycostem to participate the CAR-TCR Digital Summit Europe during 16th to 18th Feb, 2021, with workshop with our CSO Jan Spanholtz: viveNK™ products (CAR-NK and TCR-NK) as autologous CAR-T alternatives and conference presentation by our CDO Volker Huppert: clinical scale closed manufacture system for allogeneic NK products on.
Glycostem to participate on BIO CEO & Investor Digital Conference during 16th to 18th Feb, 2021, one of the biggest biotech industry networking events in the U.S.